Tempest Therapeutics (TPST) EV to CFO (2012 - 2025)

Tempest Therapeutics has disclosed EV to CFO across 14 years of filings, most recently posting 1.8 for Q4 2025.

• In Q4 2025, EV to CFO fell 361.69% year-over-year to 1.8; the TTM figure through Dec 2025 stood at 0.24 (down 213.48% YoY), while the FY2025 annual figure was 0.24, down 213.48% from the prior year.
• EV to CFO came in at 1.8 for Q4 2025 at Tempest Therapeutics, up from 5.62 in the prior quarter.
• In the past five years, EV to CFO ranged from a high of 6.86 in Q1 2021 to a low of 457.58 in Q2 2021.
• Average EV to CFO over 5 years is 22.94, with a median of 1.26 recorded in 2023.
• Year-over-year, EV to CFO soared 265.09% in 2021 and tumbled 1706.33% in 2024.
• Over 5 years, EV to CFO stood at 5.86 in 2021, then tumbled by 48.45% to 3.02 in 2022, then plunged by 253.22% to 4.63 in 2023, then soared by 114.85% to 0.69 in 2024, then plunged by 361.69% to 1.8 in 2025.
• Per Business Quant data, the three most recent EV to CFO figures were 1.8 in Q4 2025, 5.62 in Q3 2025, and 1.88 in Q2 2025.